Cargando…
Assessing the association between dipeptidyl peptidase-4 inhibitors use and celiac disease through drug adverse event reporting
Autores principales: | Li, Dandan, Silvester, Jocelyn Anne, Crowley, Matthew J., Yang, Jeff Y., Alexopoulos, Anastasia-Stefania, Xu, Yang, Zhan, Siyan, Wang, Tiansheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997957/ https://www.ncbi.nlm.nih.gov/pubmed/32071711 http://dx.doi.org/10.1177/2040622320904301 |
Ejemplares similares
-
Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting
por: Wang, Tiansheng, et al.
Publicado: (2019) -
Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
por: Li, Guangyao, et al.
Publicado: (2019) -
Health economic evaluation of dipeptidyl peptidase-4 inhibitors
por: Garg, Vishvas
Publicado: (2011) -
New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022) -
Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
por: Huang, Jing, et al.
Publicado: (2020)